Signifience • Health Data Analysis

Publications

Here are presented the most recent publications where biostatisticians from Signifience provided full statistical support

External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

Jeremie Abtan , Deepak L Bhatt , Yedid Elbez , Gregory Ducrocq , Shinya Goto , Sidney C Smith Jr , E Magnus Ohman , Kim A Eagle , Kim Fox , Robert A Harrington , Lawrence A Leiter , Shamir Mehta , Tabassome Simon , Ivo Petrov , Peter R Sinnaeve , Prem Pais , Eli Lev , Héctor Bueno , Peter Wilson , Philippe Gabriel Steg ; REACH Registry Investigators

Internal journal of Cardiology

2023 Jan 1;370:51-57. doi: 10.1016/j.ijcard.2022.10.132. Epub 2022 Oct 19.

Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention

Batric Popovic , Gregory Ducrocq , Yedid Elbez , Christoph Bode , Shamir R Mehta, Charles V Pollack , Manel Sabate , Sunil V Rao , Alexander Parkhomenko, Laurent J Feldma , Neila Sayah , Marc S Sabatine, Philippe Gabriel Steg; TAO investigators

American Journal of Cardiology.

2023 Feb 1;188:95-101. doi: 10.1016/j.amjcard.2022.11.013. Epub 2022 Dec 6.

Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES.

Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagström E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, Simon T, Steg PG

Canadian Journal of Cardiology

2022 May 26:S0828-282X(22)00337-3. doi: 10.1016/j.cjca.2022.05.021.

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study

Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA

BMC Rheumatology

2022 Apr 14;6(1):24. doi: 10.1186/s41927-022-00252-4

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.

Ahmad HA, Baker JF, Conaghan PG, Emery P, Huizinga TWJ, Elbez Y, Banerjee S, Østergaard M

Arthritis Research & Therapy

2022 Feb 16;24(1):47. doi: 10.1186/s13075-022-02735-8.

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.

Dermatology and Therapy

2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y

Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.

Alemao E, Postema R, Elbez Y, Mamane C, Finckh A.

Clin Exp Rheumatol

2020 May-Jun;38(3):455-466. Epub 2019 Nov 16. PMID: 31770089

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG

J Am Coll Cardiol.

2019 Mar 26;73(11):1362-1364. doi: 10.1016/j.jacc.2019.01.016. Epub 2019 Feb 25. PMID: 30819552

Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.

Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Röther J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators.

J Am Coll Cardiol.

2019 Jul 2;73(25):3281-3291. doi: 10.1016/j.jacc.2019.04.046. PMID: 31248549.

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis.

Philip J. Mease, Iain B. McInnes, Vibeke Strand, Oliver FitzGerald, Harris A. Ahmad, Yedid Elbez, Subhashis Banerjee

Rheumatol Int.

2019 Mar 26;73(11):1362-1364. doi: 10.1016/j.jacc.2019.01.016. Epub 2019 Feb 25. PMID: 30819552

Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry

CLARIFY investigators. Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, Ford I, Greenlaw N, Kalra PR, Parma Z, Shalnova S, Tardif JC, Tendera M, Zamorano JL, Vidal-Petiot E, Steg PG;

Eur Heart Journal

2020 Jan 14;41(3):347-356.

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, Philip J Mease

RMD Open.

Published online 2019 May

Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countrie

Alten R, Feist E, Lorenz HM, Nüßlein H, Voll RE, Chartier M, Elbez Y, Rauch C

Clin Rheumatol.

2019 Nov;38(11):3049-3059.

Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.

Alemao E, Postema R, Elbez Y, Mamane C, Finckh A.

Clin Exp Rheumatol.

2019 Nov 16

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study

Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüßlein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE.

Wien Med Wochenschr

2019 Oct 25.

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E. Voll, Yedid Elbez, Christiane Rauch

Arthritis Res Ther.

2018; 20: 1. Published online 2018 Jan 2.

Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.

Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G

Clin Exp Rheumatol.

2018 Sep-Oct;36(5):935-936

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M.

RMD Open.

2017 Dec 29;3(2):e000538

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M.

RMD Open.

2016 Feb 15;2(1):e000228.

The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients.

Vidal-Petiot E, Elbez Y, Lüscher TF, Fox KM, Steg PG.

Eur Heart J.

2018 Dec 1;39(45):4040-4041.